Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TRANSITION THERAPEUTICS INC. T.TTH

"Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company is engaged in developing therapeutics for disease indications with markets. Its technologies are focused on the treatment of Alzheimer's disease and diabetes."


TSX:TTH - Post by User

Comment by deninsaskon Aug 24, 2007 3:29pm
327 Views
Post# 13297897

RE: TTH and Hep C

RE: TTH and Hep C F7......It is no secret that the MS-IET was dropped because of Elans monotherapy drug TYSABRI. Interferon is no longer the go to drug for relapsing remitting MS. I think the HCV-IET will be held on to for quite a while........ until the Combination Therapy Pegylated Interferon/Ribavirin is replaced as the Gold Standard for HEPC because HCV-IET is piggybacked onto it. I would think that Transition will be pushing it at BioContact Quebec on Oct 3. It's not over yet for HEPC. But it has been a year since the 12 week interim results were released in Aug/06. GLA
Bullboard Posts